abs226.txt	the	2013	update	of	american	society	clinical	oncology-college	americanpathologists	(asco-cap)	human	epidermal	growth	factor	receptor	2	(her2)	testingguidelines	recommend	using	an	alternative	chromosome	17	probe	assay	to	resolveher2	results	determined	be	equivocal	by	immunohistochemistry	(ihc)	orfluorescence	in-situ	hybridization	(fish)		however	it	is	unclear	if	casesconsidered	her2-positive	(her2+)	method	are	similar	tothose	classified	as	her2+	traditional	ihc	and	fish	criteria	benefit	thesame	from	her2-targeted	therapies	we	studied	pathologicfeatures	all	31	breast	cancers	probemethod	at	our	institution	since	their	pam50	intrinsicmolecular	subtypes	for	comparison	analyzed	19	consecutive	cases	that	wereclassified	during	same	time	period	thirty	(97%)	in	cohort	were	estrogen	receptor(er)-positive	(er+)	while	only	9/19	(47%)	her2	controls	er+(p	=	0	0002)	sufficient	tissue	intrinsic	subtype	analysis	was	available	for20/31	her2+group	none	(0%)	20	probe-positive	theher2-enriched	8/9	(89%)	those	traditionalfish	her2-enriched	(p	0001)	these	findings	suggest	breastcancers	biologicallydistinct	raisesquestions	whether	or	not	they	derive	her2-targetedtherapies
